Zosano Pharma Corporation was a clinical-stage biopharmaceutical company that focused on developing and commercializing its proprietary transdermal microneedle patch system. This technology aimed to provide rapid systemic administration of drugs and biologics. Their lead product candidate, M207 (Qtrypta™), was a zolmitriptan-coated microneedle patch developed for the acute treatment of migraine. Despite promising technology, the company faced regulatory setbacks and filed for Chapter 11 bankruptcy in June 2022. Its key assets, including the microneedle technology platform, were acquired by EmergPharma Inc. in October 2022. The information presented here reflects Zosano Pharma's operational period as an independent entity.
Served as the central hub for all corporate functions, including research and development, clinical trial operations, manufacturing process development, and administrative activities.
The facility likely housed specialized laboratories for microneedle patch development, small-scale GMP manufacturing capabilities for clinical trial materials, quality control labs, and R&D labs for formulation and device engineering.
As a clinical-stage biopharmaceutical company, Zosano Pharma likely fostered a science-driven, innovative, and results-oriented work culture. Employees were focused on advancing pipeline candidates through clinical development and navigating the regulatory landscape.
This headquarters was pivotal for the innovation and development of Zosano's proprietary microneedle patch technology, particularly its lead candidate M207 for migraine treatment. All strategic decisions and core research originated from this site.
Zosano Pharma's operations were primarily concentrated in the United States, with its headquarters in Fremont, California, serving as the main center for R&D and corporate functions. While its product candidates, if approved, would have targeted global markets, the company did not have a significant physical international office presence. Its global strategy would have likely involved partnerships for international commercialization.
34790 Ardentech Court
Fremont
California
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Zosano Pharma' leadership includes:
Zosano Pharma has been backed by several prominent investors over the years, including:
In the 12-18 months leading up to its June 2022 bankruptcy filing and subsequent asset sale in October 2022, Zosano Pharma made a key commercial executive hire. The core leadership team largely remained in place through the bankruptcy proceedings, after which their roles with the Zosano Pharma entity concluded.
Discover the tools Zosano Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Zosano Pharma is no longer operating independently, its email format likely followed common corporate structures. Typical formats for pharmaceutical companies include first initial followed by last name, or first name separated by a dot from the last name.
flast@zosanopharma.com (e.g., jsmith@zosanopharma.com) or first.last@zosanopharma.com (e.g., john.smith@zosanopharma.com)
Format
sdoe@zosanopharma.com
Example
0 (Company's independent operations ceased in 2022; emails are inactive)%
Success rate
PR Newswire • October 7, 2022
EmergPharma Inc. announced its acquisition of the assets of Zosano Pharma Corporation, including its microneedle drug delivery system and related intellectual property, following Zosano's Chapter 11 bankruptcy. EmergPharma intends to continue the development of the microneedle patch technology....more
BioSpace • June 15, 2022
Zosano Pharma Corporation filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware. The company aimed to pursue a sale of its assets, citing ongoing financial constraints and regulatory setbacks....more
FierceBiotech • April 21, 2020
Zosano Pharma announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for Qtrypta™ (M207), its microneedle patch for acute migraine treatment. The CRL cited issues related to inconsistent drug exposure levels observed in studies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Zosano Pharma, are just a search away.